Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the role of imaging in the diagnosis and response assessment of patients with myeloma and describes new diagnostic requirements. Dr Zamagni talks on the minimal requirement for diagnosis staging of myeloma, which is performed using whole-body low-dose computed tomography (WBLDCT), as well as the benefits of positron emission tomography (PET)-computed tomography (CT) and diffusion-weighted magnetic resonance imaging (MRI). Dr Zamagni also talks on the use of PET-CT and diffusion-weighted MRI and other novel techniques for the assessment of measurable residual disease (MRD). This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

свернуть